Eight multiple myeloma patients participated in a phase I trial evaluating the feasibility and safety of subcutaneous vaccination with adenovirus engineered, autologous plasma cells after high-dose therapy. Plasma cells were concentrated from bone marrow harvests by negative selection and high gradient magnetic separation. The mean plasma cell yield was 2.61 × 10 
Introduction
High-dose chemotherapy followed by stem cell transplantation has increased complete remission rates, event free and overall survival in myeloma, but has not resulted in long-term disease free survival. 1, 2 Despite continued refinement of chemoradiotherapy conditioning regimens 3 and the development of purging techniques, 4, 5 persistence of clonal myeloma cells post-transplant remains a major problem. One novel approach to reduce relapses after high-dose chemotherapy may be to intensify immune-mediated effector mechanisms against myeloma cells and thereby eliminate minimal residual disease. Such anti-tumor responses could theoretically be induced by the transfer of immunostimulatory genes into autologous plasma cells for subsequent patient vaccination.
In support of this approach several lines of evidence suggest that immunomodulation is of potential therapeutic value in myeloma. Most compelling are reports from clinical studies that have demonstrated myeloma responses following donor lymphocyte infusions in patients relapsing after allografting. 6, 7 Further supporting the ability to generate tumor specific immune responses, Kwak et al 8 time of allografting. Although the results of allogenic cellmediated adoptive immunotherapy are therefore encouraging, such approaches are limited by the availability of suitable donors. Alternatively, immunization of myeloma patients against their own idiotype is now being explored. While studies using autologous idiotype for vaccination have demonstrated in vitro immunologic responses few significant clinical responses using this strategy alone have been reported to date. [9] [10] [11] Given the limitations of idiotype vaccines and the potential for other as yet unrecognized tumor-associated antigen expressed on myeloma cells, 12, 13 we have instead explored the use of autologous, genetically engineered, irradiated plasma cells modified to express immunostimulatory genes.
To invoke an autologous immune response to tumor cells a number of cytokines, including interleukin (IL)-2, have been shown to be effective. 14, 15 Preclinical and clinical studies demonstrate the susceptibility of malignant plasma cells to in vitro and in vivo cytotoxic effector mechanisms induced by IL-2. 16, 17 Furthermore, systemic administration of IL-2 has been shown to induce clinical responses in hematological malignancies, but with significant toxicity. 18 It follows that injection of IL-2 secreting autologous plasma cells into patients, in contrast to systemic IL-2 administration, should localize the effector cytokine at the site of antigen presentation and prove less toxic. There is evidence that IL-2 in the tumor microenvironment promotes CTL activation without CD4 helper function 19 and that local levels of secreted IL-2 correlate with both systemic and local anti-tumor responses. 20 Indeed, an immune response to IL-2 expressing retrovirus gene modified plasma cells has been generated in an animal model of myeloma. 21 Even more encouraging is a recent study in neuroblastoma patients demonstrating systemic anti-tumor activity and clinical responses following immunization with IL-2 expressing, adenovector infected, autologous tumor cells. 22 On the basis of these preclinical and clinical studies we initiated a phase I trial of AdCAIL-2 engineered autologous plasma cell vaccination in patients with minimal residual myeloma following high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT).
Materials and methods

Clinical protocol and study design
The primary objectives of this phase 1 trial were to evaluate the technical feasibility of autologous plasma cell vaccine production and to determine the safety and toxicity of clinical administration. The clinical protocol was approved by the University of Toronto and by the Health Protection Branch of Canada. The protocol is schematically described in Figure 1 . All patients signed consent to undergo autologous gene-modi-
Figure 1
Schema of gene therapy protocol.
(1) Obtain bone marrow harvest prior to induction chemotherapy; (2) purify plasma cells from bone marrow mononuclear cells by negative selection and high gradient magnetic separation; (3) infect purified plasma cells with AdCAIL-2; (4) cryopreserve gene-modified plasma cells and reserve aliquot for testing of IL-2 secretion, sterility, RCA and viability. (5) Meanwhile, patient receives induction chemotherapy, followed by high-dose chemotherapy and PBSCT; (6) 2 months after transplant, the patient is vaccinated with IL-2 secreting plasma cells; (7) cells are thawed, irradiated and injected subcutaneously on days 1, 14 and monthly thereafter depending on the number of vaccines available for each patient.
fied tumor vaccine administration following high-dose chemoradiotherapy.
Patients
Eligibility for the trial required laboratory, histopathologic, and radiologic findings consistent with the diagnosis of Durie-Salmon stage II or III multiple myeloma. Patients were enrolled at the time of assessment for high-dose chemo-radiotherapy. Entry criteria included a bone marrow plasmacytosis of у20% in aspirates obtained at the time of initial assessment. Induction chemotherapy consisted of at least 3, but no more than 6 months of prior chemotherapy to produce disease control, with no more than 3 months of prior therapy consisting of the alkylating agent melphalan (Mel). Patients having demonstrated stable or chemosensitive disease proceeded to stem cell transplant followed by vaccination. PBSC were collected after a single treatment of cyclophosphamide (2.5 g/m 2 ) followed by granulocyte-stimulating growth factor (G-CSF) and used for transplantation. The transplant conditioning regimen consisted of melphalan 160 mg/m 2 , etoposide 60 mg/kg and fractionated total body irradiation (TBI), 12 Gy. Partial responses (PR) to high-dose therapy were defined as a reduction of the serum monoclonal spike by greater than 50% of the pretreatment value and a 75% reduction of Bence-Jones proteinuria. Complete responses (CR) were defined as the repeated absence of a monoclonal immunoglobulin by immunofixation and no evidence of clonal plasma cells in bone marrow specimens.
Autologous vaccine production
Plasma cell vaccines were prepared from 600-1000 ml of bone marrow harvested under general anesthetic. MonoLeukemia nuclear cells (MNC) were isolated on Percoll gradients, red cells were lysed (155 mm ammonium chloride, 10 mm potassium bicarbonate and 1 mm EDTA) and residual MNCs washed in sterile phosphate buffered saline (PBS). An aliquot of cells was removed for assessment of total cell number and plasma cell content. To satisfy regulatory requirements, a negative selection method of plasma cell isolation was employed. Plasma cells were separated from MNCs by high gradient magnetic separation (Stemsep, Stemcell Technologies, Vancouver, Canada). In brief, MNCs were resuspended at a concentration of 5 × 10 7 /ml in 10 ml sterile PBS/2.5% human albumin (HA) and incubated on ice with a 1-ml cocktail of tetrameric mouse monoclonal antibodies (anti-CD14, anti-CD33, anti-CD41, anti-CD66, anti-CD45RA and anti-glycophorin: Stemcell Technologies). These tetrameric antibodies are bispecific crosslinkers, which bind both the described cell surface antigens and dextran. After a 30-min incubation, 0.6 ml of magnetic colloid dextran iron was added to the cellantibody suspension and the final volume adjusted to 20 ml with PBS/2.5% HA. After a further 30-min incubation on ice, the cell suspension was processed through the Stemsep device for the depletion of the antibody labeled cells according to the manufacturer's instructions. The unlabeled plasma cells were collected in the eluate, washed and resuspended in RPMI 1640 (Gibco BRL, Grand Island, NY, USA). An aliquot of cells was removed for assessment of cell number, viability and plasma cell content. If sufficient cells were recovered, samples were archived for later use as stimulator/target cells for immune assays. The composition of the plasma cell preparation pre-and post-negative selection was assessed by both light microscopy and flow cytometry. For flow cytometric assessment, PE-or FITC-labeled anti-CD38 and -CD45RA monoclonal antibodies (Becton Dickinson, Mountain View, CA, USA) were used to enumerate plasma cells. Flow cytometry was performed on a FACScan (Becton Dickinson, Meylan, France) using Cell Quest software to acquire data and ModFit LT software for analysis. The percentage of cells with low side scatter, high CD38 expression and dim expression of CD45RA was defined as the plasma cell population.
Gene transfer and efficiency
AdCAIL-2 has previously been used in our breast cancer and melanoma trials and the construct, production and activity have been described. 23 Clinical grade AdCAIL-2 viral supernatant is packaged at 1 × 10 10 pfu/ml and contains 1-10 pfu of detectable wild-type virus in 10 9 plaque-forming units (pfu) of vector. Purified plasma cells were infected with this adenovirus at a multiplicity of infection (MOI) of 10-20 in T75 flasks (Fisher, Mississauga, Ontario, Canada) for 1-2 h. Adenovirus modified cells were centrifuged, washed twice in PBS and cryopreserved at a maximum of 1 × 10 8 cells/5-ml cryovial. The final freezing solution consisted of 7.5% dimethyl sulfoxide (DMSO) (Research Industries, Salt Lake City, UT, USA), 4% heparin and 2% HA. Cryopreservation was carried out in a Cobe controlled rate freezer and vaccines were stored at −150°C. Prior to cryopreservation, an aliquot of cells from each vaccine underwent viability testing, microbiological screening and testing for IL-2 expression after 24-48 h in culture. The concentration of human IL-2 in the supernatant of the AdCAIL-2-infected plasma cell cultures was measured by ELISA employing the Quantikine Human IL-2 ELISA kit (R&D Systems, Minneapolis, MN, USA).
Vaccine administration
For vaccination, cells were thawed rapidly at 37°C, centrifuged, washed once, diluted in a final volume of 1 ml of PBS and irradiated with 50 Gy. This dose of radiation renders AdCAIL-2-infected U266 myeloma cell lines incapable of proliferation while having minimal effect on IL-2 secretion by the gene modified cells (data not shown). Viability testing was performed on the thawed unirradiated cells. The first subcutaneous injections of the cellular vaccine were administered 60 days after stem cell transplantation as both pre-clinical and clinical studies support host immune reconstitution as early as 2 months post-PBSCT. 24 Patients were premedicated with benadryl and acetaminophen prior to vaccination. Our pretrial objective was to administer a minimum of three vaccines of 5 × 10 7 cells per patient. This dose was based on the likely number of cells recovered from bone marrow harvests as determined from small scale pre-clinical studies rather than on scientific data, which were not available at the time the trial was designed. The vaccine cell dose actually administered was based on the number of plasma cells recovered and ranged from 3.5-9.0 × 10 7 gene-modified autologous plasma cells. All injections were given subcutaneously. Patients receiving multiple vaccinations were injected on days 0, 14 and monthly thereafter.
Lymphocyte proliferative response to adenovirus modified tumor cells
Ex vivo autologous T cell proliferative responses to genemodified and unmodified autologous plasma cells were studied. Blood was collected from patients prior to initiation of therapy and at 2 months post-transplant. Peripheral blood lymphocytes (PBLs) were separated by Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala, Sweden) density centrifugation and stored in liquid nitrogen. PBLs from each time point were evaluated in the same assay for any one patient. Purified primary plasma cells, obtained pre-and postAdCAIL-2 infection were irradiated with 50 Gy and used as stimulator cells. The proliferation of patient PBLs in response to autologous tumor cells was measured by resuspending lymphocytes in AIM-V culture medium (Gibco BRL, Grand Island, NY, USA) and plating 10 5 cells per well in flat-bottomed 96-well microtiter plates (Fischer). Adenovirus infected and noninfected purified plasma cells were added at 5000 cells per well for a final volume of 200 l. Negative controls included PBLs or tumor cells alone. Positive controls included PBLs cultured with phytohemmaglutinin (PHA; Gibco BRL, Grand Island, NY, USA). All groups were plated in triplicate. The cells were incubated for 6 days at 37°C with 5% CO 2 and then pulsed with 0.5 Ci of 3 H-thymidine (Dupont, New England Nuclear, Boston, MA, USA). Cells were harvested 16 h later and counted in a scintillation counter. The mean counts per minute (cpm) were calculated for triplicate measurements. Data were analyzed after conversion to proliferation indices (P.I.). P.I. = (cpm of responder PBLs + stimulator tumor cells) − (cpm of tumor cells alone)/(cpm of PBLs in culture alone).
Phenotyping of local lesions
Skin biopsies were obtained from patients demonstrating local reactions 24-72 h after vaccine administration. The primary antibody reagents used were rabbit polyclonal anti-human CD3, and monoclonal anti-CD4 (clone OPD4), -CD20 (clone L26), -CD68 (clone PG-M1) (all from Dako, Carpenteria, CA, USA); anti-CD8 (clone 4B11) (Novocastra Laboratories, Newcastle-upon-Tyne, UK); anti-CD56 (Zymed Laboratories, San Francisco, CA, USA) and anti-TIA-1 (Coulter-Immunotech, Marseille, France) a marker for cytotoxic granules expressed in NK cells and cytotoxic T lymphocytes (CTLs).
Anti-adenovirus antibody titers
Baseline serum samples and samples taken at follow-up visits were analyzed for anti-adenovirus titers by ELISA as previously described. 23 
Generation of CTL responses and assessment of IFN-␥ release
Autologous plasma cell specific CTL killing was measured by 
Measurement of systemic IL-2
Serum samples cryopreserved before and 3 days after vaccination were analyzed for IL-2. 200 l of serum was tested by ELISA using the kits described above.
Results
Patient description
Eight patients with multiple myeloma treated at our institution were enrolled in this phase I cellular vaccine study for patients with minimal disease. Details of patient demographics, disease characteristics and prior treatment modalities are summarized in Table 1 . At the time of enrollment seven patients were clinical stage III disease and one was stage II. Vaccines were made if at the time of initial assessment bone marrow aspirates contained у20% plasma cells. Seven patients received highdose therapy consisting of melphalan, etoposide and TBI followed by PBSCT; patient 2 did not undergo PBSCT as a result Leukemia of an inadequate stem cell collection. 3 Three of the transplanted patients achieved a CR after high-dose therapy. One patient died of complications of transplant prior to being vaccinated.
Vaccine production
Plasma cells were isolated from bone marrow MNCs by negative selection and high gradient magnetic separation. Using this method, malignant plasma cells were enriched an average of 3.5-fold resulting in a final cell population consisting of 18-90% plasma cells (mean 68.2% ± 28.4%) ( Table 2) as assessed by light microscopy and flow cytometry (Figure 2 ). The total cell number recovered from initial bone marrow harvests of 600-1000 ml, contaminated with 8-34% malignant cells presort, averaged 2.61 × 10 8 (range 0.07-9.0 × 10 8 ). The disparity between the plasmacytosis observed in initial assessment bone marrow aspirates compared with the plasma cell content of bone marrow harvests procured for vaccine production likely reflects blood dilution of the large volume harvest. The viability of plasma cells, after negative selection but before AdCAIL-2 infection, was 88.5% ± 6.8% while the cell viability after cryopreservation and at the time of vaccine administration was 65.8% ± 4.2% (range 41%-81%). The efficiency of our purification method was low with an overall recovery of plasma cells of only 32.2% (range 10-46%). Although only one of eight plasma cell collections yielded too few cells for vaccine production (PCV002), we recovered sufficient plasma cells for the production of multiple vaccines from only three marrow harvests (Table 3) . Patient 2 not only had insufficient cells for vaccine production; this same patient had an inadequate stem cell collection for PBSCT.
After purification, plasma cells were infected with an adenovirus expressing the immunostimulatory transgene, IL-2. We tested for in vitro secretion of IL-2 from plasma cell cultures by ELISA, 24 h (mean 1.16 ± 0.46 ng/ml/10 6 cells) or 48 h after infection (mean 2.95 ± 1.50 ng/ml/10 6 cells). We next tested ex vivo T cell proliferative responses to autologous purified plasma cells, pre-and post-AdCAIL-2 infection, in five patients. Significant enhancement of autologous lymphocyte proliferation was observed in response to the gene-modified tumor cells as compared to unmodified plasma cells indicating the capacity of autologous lymphocytes to respond to IL-2 secreting plasma cells 60 days after PBSCT (Figure 3) . Although it is possible that this response was mediated by the adenovector itself, pre-clinical studies demonstrated no increase in allogeneic T lymphocyte proliferation in response to cell lines infected with a control adenovirus as compared to uninfected myeloma cells. In contrast, AdCAIL-2 infected cell lines elicited a marked enhancement of T lymphocyte proliferative responses. 25 
Vaccine administration
Six of eight patients received between one and five subcutaneous vaccinations of 3.5-9.0 × 10 7 irradiated autologous IL-2 secreting plasma cells. One patient (patient 4) died after highdose therapy before the vaccine could be administered and patient 2 had insufficient plasma cells collected for vaccine production. The vaccine was locally and systemically well tolerated with no patient experiencing serious adverse events or complications. Minor systemic symptoms followed three injections and consisted of flu-like symptoms (patient 7) and generalized rash (patients 5 and 8). These side-effects were transient and did not require intervention. No renal, hepatic, pulmonary, hematological, gastrointestinal or neurological toxicities were observed and no patient exhibited symptoms suggestive of an autoimmune disease. In no instances did adverse reactions necessitate a dose reduction of the vaccine or the discontinuation of the study. Replication-competent adenovirus or shed adenovector was not detected in the blood or saliva of any patient using PCR as previously described. 23 
Local immune response
Injection of autologous, IL-2-secreting plasma cells evoked modest local reactions in two patients. There was no correlation between patients who demonstrated a local response (patients 3 and 6) and the cell dose administered or the level of IL-2 secreted. Clinically, the reactions were characterized by erythema and induration and were apparent by 24 h and maximal at 72 h after injection. Biopsies of injection sites were characterized histologically by an infiltrate of T lymphocytes marking for CD3, CD8 and TIA-1, a marker of cytotoxic T cell activity (Figure 4 ).
Systemic immune responses
Assessments of the patient's general immune status disclosed no vaccine-induced changes in number or phenotype of circulating T lymphocytes as assessed by flow cytometric analysis. We observed a persistent decrease in circulating CD4 and CD8 counts and an inversion of the CD4/CD8 ratio in all patients who received high-dose therapy. However, the mean number and proportion of CD4 and CD8 cells changed little compared to pre-immunization values. No consistent changes in post-vaccination circulating monocyte or eosinophil counts were noted among the study population. Serum IL-2 levels measured pre-and 3 days post-injection, did not significantly change in any of the patients tested (n = 5). Four patients were tested and were negative for the presence of anti-nuclear antibodies and rheumatoid factor both before and after completion of vaccination. We also investigated whether the injection of gene-modified tumor cells generated an anti-adenovirus response. Antiadenovirus IgG were measured at baseline, with each injection and 3-4 weeks after each innoculation. Three of the five patients studied, including one patient who received multiple injections, showed no significant increase in antibody titers (Table 4) . Two patients demonstrated a minor increase in antiadenoviral units from 291.3 to 658.3 (patient 3) and 16.0 to 89.2 (patient 6), pre-first injection and post-last injection, respectively. Neither of these patients exhibited systemic symptoms, however of interest both demonstrated local inflammatory responses.
Planned tumor-specific immune studies were limited by the small number and poor viability of purified plasma cells used as both simulator and target cells in lymphocyte proliferation and CTL assays and were therefore not informative in the majority of patients. After negative selection, sufficient viable plasma cells were retained from patient 6 to assess for cytotoxic T cell responses. We did not observe an increase in myeloma specific CTL activity in this patient, as discerned by direct killing, at any time during the observation period. Furthermore, we demonstrated only a minor increase in post-vaccination lymphocyte IFN-␥ release (0.4 pg/ml to 1.2 pg/ml) in response to autologous tumor cells.
Clinical outcome
The median follow-up for the patient population was 15 months (range, 8-27 months) post-PBSCT. Of the six vaccinated patients all are alive and four continue to have stable disease. Two patients have maintained a CR at 8 months (patient 6) and 12 months (patient 8) post-transplant. Patient 1 developed a new amyloidoma 14 months after PBSCT and patient 7 was noted to have increasing proteinuria 12 months after high-dose therapy. Of the six patients vaccinated, three achieved a CR with stem cell transplant and two had nonsecretory disease leaving only one patient with measurable disease at the time of vaccination. This patient has not demonstrated a decrease in monoclonal protein after immunization. The patient who failed to undergo PBSCT and vaccination (patient 2) progressed 9 months after enrollment into the study and patient 4 died within 1 month of autologous stem cell transplant of an acute myocardial infarction.
Discussion
Multiple myeloma remains incurable using conventional therapies raising the need for alternate treatment strategies. A strategy being evaluated by a number of groups is the use of immunologic approaches to treat myeloma after high-dose therapy. To date such clinical trials have generally employed idiotype vaccines to induce anti-tumor responses. 10, 11, 26, 27 An alternative approach, using gene-modified plasma cells, has been explored in animal models 21 and in vitro 28 by several groups, however clinical studies of this approach have not yet been reported.
The use of autologous cytokine-secreting plasma cell vaccines to treat myeloma first presents the challenge of isolating primary tumor cells from the patients. A positive selection technique for isolating plasma cells using anti-CD138 mAb has been described and is highly effective. 29 Nonetheless, we felt that a negative selection procedure wherein residual cells are unlabelled by antibody would generally be more acceptLeukemia able to regulatory authorities in view of the lack of appropriate good manufacturing practice (GMP) quality antibodies. Following promising small scale preclinical studies we decided to employ a negative selection technique utilizing high gradient magnetic separation. Using this negative selection procedure it was possible to generate plasma cell vaccines for 88% of the study population. However, as a result of inadequate plasma cell recovery only three patients received the pre-scheduled number of immunizations. The relatively low yield of plasma cells and the variability of plasma cell purity may reflect the low starting plasma cell content in bone marrow samples or the inappropriate expression of cell surface antigens identified in the antibody cocktail on the surface of some myeloma cells. 30 Nevertheless, the number of cells injected per vaccine and the IL-2 secreted by gene modified plasma cells was comparable to that employed by other groups in melanoma and neuroblastoma trials. 22, 31, 32 These studies each reported efficacy as defined by vaccine-induced anti-tumor responses and/or clinical responses.
In contrast to the technical limits of plasma cell isolation, transfer of the IL-2 gene into myeloma cells was readily accomplished with a single transduction. Although the lack of reporter gene in our adenovector constructs renders it impossible to define what percentage of plasma cells were infected with virus we believe that plasma cells were the primary target of infection. In pre-clinical studies we demonstrated efficient (mean 33%) adenovirus-mediated gene transfer into malignant plasma cells in the majority (84%) of myeloma patients tested. 33 Furthermore, several groups have reported increased sensitivity of malignant plasma cells to adenovirus-mediated 853 Overall, autologous plasma cell vaccines were well tolerated with no serious acute or long-term systemic toxicities reported. Our results however, do not demonstrate clinical responses of bulk tumor reduction. Patient immune parameters studied in this trial, although limited, reveal only minimal effects of vaccine administration. Examination of specific anti-tumor immune responses were significantly restricted by the difficulties encountered in obtaining and sustaining sufficient viable primary myeloma cells. In the one fully evaluable patient we did not observe a significant increase in myeloma specific anti-tumor immunity, as assessed by both IFN-␥ release and CTL killing of autologous plasma cells in this patient. The relative lack of immune or clinical efficacy seen in this trial may reflect an inadequate cell dose, inadequate transgene expression level, use of irradiated cell vaccines, rate and route of delivery or inefficiency of such strategies in general. Further preclinical and clinical studies will be required to address these issues.
In summary, although further studies are necessary to examine the immune-stimulating potential and clinical effectiveness of immunogene therapy of multiple myeloma, this trial does demonstrate that the method of vaccine production described is feasible and the treatment is associated with little toxicity. However, the selection procedure employed is labor intensive and of low efficiency with less then half the patients receiving the scheduled number of vaccines. To circumvent this problem alternatives include use of positive selection 29 or use of whole unsorted, but tumor contaminated bone marrow. The resulting access to larger cell populations would allow for dose escalation studies. It is hoped that the combination of more potent immune-stimulating genes, higher delivered cell dose and optimal delivery routes in ongoing studies will provide further insight into the clinical potential of this approach to myeloma therapy.
